Persista Bio is a preclinical biotherapeutics company developing the O2Line oxygenated long-term cell implant system, designed to regulate blood sugar automatically for people with Type 1 diabetes without immunosuppression or daily injections, pumps or finger sticks. The company licenses foundational encapsulation technology from Cornell University and enabling oxygenation technology from Giner.
Advance preclinical work in a large animal (porcine) model and scale up manufacturing
Further FDA meetings following positive INTERACT feedback
Through a recent INTERACT meeting with the FDA's Center for Biologics Evaluation and Research, Persista Bio received positive feedback on its modular approach to developing an implantable cell therapy system for Type 1 diabetes.
Co-Founder and Chief Executive Officer
Scientific Co-Founder